The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

June 24, 2022

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial.

June 21, 2022

Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.

June 21, 2022

Guadecitabine did not result in a statistically significant improvement in overall survival compared with physician’s choice of treatment in patients with relapsed/refractory myelodysplastic syndrome or chronic myelomonocytic leukemia, according to data from the phase 3 ASTRAL-3 trial.

June 15, 2022

The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.

June 13, 2022

Nicholas J. Short, MD, discusses updated results from a single-arm phase 2 study investigating ponatinib plus blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

June 13, 2022

Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the current ongoing research he’s eager to see reported.

June 11, 2022

The triplet combination regimen comprised of quizartinib, decitabine, and venetoclax elicited encouraging responses in heavily pretreated patients with relapsed/refractory FLT3-ITD–mutated acute myeloid leukemia who were previously exposed to a FLT3 inhibitor.

June 11, 2022

Musa Yilmaz, MD, discusses composite complete remission and bone marrow transplant rates observed in a phase 1/2 trial in patients with FLT3-ITD–mutated acute myeloid leukemia.

June 11, 2022

Momelotinib demonstrated significant improvements in symptoms, spleen size, and anemia measures compared with danazol in patients with symptomatic and anemic myelofibrosis who previously received treatment with a JAK inhibitor.

June 09, 2022

Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.

June 09, 2022

Samer Srour, MD, discusses his experiences with the Orca-T and Orca-Q programs, and highlights how this type of treatment is shifting the field of hematologic malignancies.

June 07, 2022

A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.

June 06, 2022

The combination of lasofoxifene and abemaciclib provided a meaningful progression-free survival benefit and elicited encouraging responses with an acceptable toxicity profile in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

June 05, 2022

Extended follow-up data from the LIBRETTO-001 demonstrated that selpercatinib elicited durable responses in patients with RET fusion-positive solid tumors, including refractory gastrointestinal malignancies.

June 04, 2022

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

June 03, 2022

Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.

June 02, 2022

Jaffer A. Ajani, MD, discusses how the FDA approvals of first-line nivolumab plus chemotherapy and nivolumab plus ipilimumab in advanced or metastatic esophageal squamous cell carcinoma will improve treatment in this setting.

June 02, 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

May 31, 2022

Ishwaria M. Subbiah, MD, MS, brings attention to the perpetrators of sexual harassment, outlines the nuances of how these experiences affect personal wellbeing and job satisfaction, and highlights the need for accountability as a first step toward systemic change across the oncology community.

May 25, 2022

The safety and efficacy of encorafenib plus cetuximab with or without standard-of-care chemotherapy will be compared with that of chemotherapy alone in patients with BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial.